nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

17.09.2021 | Original Article – Clinical Oncology

Comparing strategy of immune checkpoint inhibitors plus chemotherapy with chemotherapy alone for small cell lung cancer: a meta-analysis based on six RCTs incorporating 2800 participants

verfasst von: Yaqi Zhong, Qing Wu, Sumei Wu, Xianhe Xie

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The project is designed to compare the clinical efficacy and adverse events resulting from immune checkpoint inhibitors (ICIs) plus chemotherapy and chemotherapy alone in patients with small cell lung cancer (SCLC).

Methods

PubMed Database and ClinicalTrials.gov were both searched to identify randomized controlled clinical trials for assessing ICIs in all-stage SCLC. After screening in strict accordance with the inclusion and exclusion criteria, eligible studies were evaluated in regard to the population, intervention, comparator, outcome as well as study design (PICOS) pattern. Furthermore, primary endpoints of these randomized controlled trials (RCTs) included overall survival (OS), progression-free survival (PFS) and complete/objective response rate (CRR/ORR). Statistical analyses were realized via Review Manager Version 5.3 Software.

Results

Compared with the chemotherapy alone group, the ICIs plus chemotherapy group significantly improved with respect to such indicators as OS (hazard ratio (HR) = 0.82, 95% CI 0.74–0.90, P < 0.0001), PFS (HR = 0.80, 95% CI 0.74–0.87, P < 0.00001) and ORR (64.7% versus 59.1%). According to the safety analysis, the incidence of treatment-related adverse events (trAEs) at all grades was higher in ICIs plus chemotherapy group (OR = 1.59, 95% CI 1.20–2.10, P = 0.001), bearing no statistical significance at grade 3 or above (OR = 1.21, 95% CI 0.99–1.49, P = 0.07).

Conclusions

The combination of ICIs and chemotherapy witnessed better anti-neoplastic efficacy for SCLC. Moreover, the incidence of trAEs at all grades was elevated in ICIs plus chemotherapy group, with little discrepancy in both groups at grade 3 or above.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global Cancer statistics Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492CrossRefPubMed

Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39(1):98–106. https://doi.org/10.1097/COC.0000000000000239CrossRefPubMedPubMedCentral

Calles A, Aguado G, Sandoval C, Álvarez R (2019) The role of immunotherapy in small cell lung cancer. Clin Transl Oncol 21(8):961–976. https://doi.org/10.1007/s12094-018-02011-9CrossRefPubMed

Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4(5):336–347. https://doi.org/10.1038/nri1349CrossRefPubMed

Facchinetti F, Di Maio M, Tiseo M (2020) Adding PD-1/PD-L1 Inhibitors to chemotherapy for the first-line treatment of extensive stage small cell lung cancer (SCLC): a meta-analysis of randomized trials. Cancers (basel). https://doi.org/10.3390/cancers12092645CrossRef

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. https://doi.org/10.1002/ijc.29210CrossRefPubMed

Fife BT, Bluestone JA (2008) Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 224:166–182. https://doi.org/10.1111/j.1600-065X.2008.00662.xCrossRefPubMed

Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al (2021) Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, Phase 3 Trial. Lancet Oncol 22(1):51–65. https://doi.org/10.1016/s1470-2045(20)30539-8CrossRefPubMed

Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A et al (2006) Changing epidemiology of small-cell lung cancer in the united states over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28):4539–4544. https://doi.org/10.1200/jco.2005.04.4859CrossRefPubMed

Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL et al (2012) Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150(6):1121–1134. https://doi.org/10.1016/j.cell.2012.08.024CrossRefPubMedPubMedCentral

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220–2229. https://doi.org/10.1056/NEJMoa1809064CrossRefPubMed

Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704. https://doi.org/10.1146/annurev.immunol.26.021607.090331CrossRefPubMed

Leal T, Wang Y, Dowlati A, Lewis DA, Chen Y, Mohindra AR et al (2020) Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination with Nivolumab as Frontline Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC): ECOG-ACRIN EA5161. J Clin Oncol 38(15):9000–9000. https://doi.org/10.1200/JCO.2020.38.15_suppl.9000CrossRef

List M, Jamous F, Gupta A, Huntington M (2015) Anti-Hu positive antibodies and small cell carcinoma: a single center review. S D Med 68(6):251 (253–5)PubMed

Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS et al (2018) Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer 101:114–122. https://doi.org/10.1016/j.ejca.2018.06.033CrossRefPubMed

Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N et al (2021) Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 39(6):619–630. https://doi.org/10.1200/jco.20.01055CrossRefPubMedPubMedCentral

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26(12):2375–2391. https://doi.org/10.1093/annonc/mdv383CrossRefPubMedPubMedCentral

Oronsky B, Reid TR, Oronsky A, Carter CA (2017) What’s new in SCLC? a review. Neoplasia 19(10):842–847. https://doi.org/10.1016/j.neo.2017.07.007CrossRefPubMedPubMedCentral

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, Phase 3 Trial. Lancet 394(10212):1929–1939. https://doi.org/10.1016/s0140-6736(19)32222-6CrossRefPubMed

Paz-Ares LG, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al (2020) Durvalumab ± Tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): updated results from the Phase III CASPIAN Study. J Clin Oncol 38(15):9002–9002. https://doi.org/10.1200/JCO.2020.38.15_suppl.9002CrossRef

Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R et al (2013) Lpilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase 2 Trial. Ann Oncol 24(1):75–83. https://doi.org/10.1093/annonc/mds213CrossRefPubMed

Reck M, Luft A, Szczesna A, Havel L, Kim S-W, Akerley W et al (2016) Phase III randomized trial of lpilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 34(31):3740–3748. https://doi.org/10.1200/JCO.2016.67.6601CrossRefPubMed

Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T et al (2020a) KEYNOTE-604: Pembrolizumab (Pembro) or Placebo Plus Etoposide and Platinum (EP) as First-Line Therapy for Extensive-Stage (ES) Small-Cell Lung Cancer (SCLC). J Clin Oncol 38(15):9001–9001. https://doi.org/10.1200/JCO.2020.38.15_suppl.9001CrossRef

Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T et al (2020b) Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, Phase III KEYNOTE-604 Study. J Clin Oncol 38(21):2369–2379. https://doi.org/10.1200/jco.20.00793CrossRefPubMedPubMedCentral

Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67(1):7–30. https://doi.org/10.3322/caac.21387CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2019) Cancer Statistics, 2019. CA Cancer J Clin 69(1):7–34. https://doi.org/10.3322/caac.21551CrossRefPubMed

Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D et al (2019) Cancer Screening in the United States, 2019: a review of Current American Cancer Society Guidelines and Current Issues in Cancer Screening. CA Cancer J Clin 69(3):184–210. https://doi.org/10.3322/caac.21557CrossRefPubMed

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB et al (2015) The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol 10(9):1243–1260. https://doi.org/10.1097/jto.0000000000000630CrossRefPubMed

Wang S, Tang J, Sun T, Zheng X, Li J, Sun H et al (2017) Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci Rep 7(1):1339. https://doi.org/10.1038/s41598-017-01571-0CrossRefPubMedPubMedCentral

Winston W, Tan M, FACP (2021) Small Cell Lung Cancer (SCLC). https://emedicine.medscape.com/article/280104-overview#a5. Accessed Mar 23 2021.

Yangqiu Li Y-LW (2016) Immunotherapy for small-cell lung cancer. Lancet Oncol. https://doi.org/10.1016/s1470-2045(16)30159-0CrossRefPubMed

Zhang S, Li S, Cheng Y (2020) Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: a systematic review and meta-analysis. Thorac Cancer 11(12):3536–3546. https://doi.org/10.1111/1759-7714.13698CrossRefPubMedPubMedCentral

Zimmerman S, Das A, Wang S, Julian R, Gandhi L, Wolf J (2019) 2017–2018 scientific advances in thoracic oncology: small cell lung cancer. J Thorac Oncol 14(5):768–783. https://doi.org/10.1016/j.jtho.2019.01.022CrossRefPubMed

Titel: Comparing strategy of immune checkpoint inhibitors plus chemotherapy with chemotherapy alone for small cell lung cancer: a meta-analysis based on six RCTs incorporating 2800 participants
verfasst von: Yaqi Zhong
Qing Wu
Sumei Wu
Xianhe Xie
Publikationsdatum: 17.09.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2022
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-021-03798-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Comparing strategy of immune checkpoint inhibitors plus chemotherapy with chemotherapy alone for small cell lung cancer: a meta-analysis based on six RCTs incorporating 2800 participants

Abstract

Objectives

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2022

Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients

Non-melanoma skin cancer diagnosis: a comparison between dermoscopic and smartphone images by unified visual and sonification deep learning algorithms

Impact of preoperative chemotherapy on pathologic nodal status in muscle-invasive bladder cancer: optimal lymphadenectomy in the preoperative chemotherapy era

Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinoma

Liquid biopsy: early and accurate diagnosis of brain tumor

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie